Clinical Trials
3 trialsNCT01945021 2021-02-21
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
Pfizer
Phase 2 Completed
NCT00932451 2017-01-13
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Pfizer
Phase 2 Completed
NCT01500824 2013-02-25
A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 2 Withdrawn